GW Pharmaceuticals (GWPH) Breathtaking Findings; Global Payments (GPN) Price Target Adjusted


Shares of GW Pharmaceuticals PLC (Nasdaq:GWPH) surged more than 5% in pre-market trade Thursday following reports indicating that its cannabidiol treatment Epidiolex was safe, well tolerated and helped reduce seizure frequency for most patients with treatment-resistant epilepsy in a study

GWPH stock touched a new 52-week low of $64.78 in the last trading session, to finally close at $67.10, up $2.14 (or +3.29%). 443,692 shares of the company exchanged hands during the day

GW Pharmaceuticals, which engages in discovering, developing, and commercializing cannabinoid prescription medicines, has 21.76M Shares Outstanding, Market Capitalization (intraday) of $1.46B and GWPH stock 52-week range is between $64.78 and $133.98 per share



Brokerage firm Topeka Capital Markets has raised its price target on Global Payments Inc. (NYSE:GPN) stock from $58.00 to $66.00, while maintaining a Hold rating

The company recently said that it expects fiscal 2016 earnings per share to be in a range of $2.90 to $3.00

Global Payments, a leading worldwide provider of payment technology services, has 129.28M Shares Outstanding, Market Capitalization (intraday) of $8.48B and GPN stock one-year range is from $38.87 to $74.64 per share


Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. GalaxyStocks is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read full disclaimer at